Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 19Head & Neck 17Thoracic 3Tumor-Agnostic 2Gynecologic 2Other solid neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × nedaplatin × Tumor-Agnostic × Clear all
NCT02777788 2017-10-10

TCM

Shanghai University of Traditional Chinese Medicine

Phase 2/3 Unknown
120 enrolled
Tumor-Agnostic

Neoplasms

NCT02088515 2017-03-03

Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 4 Completed
290 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡